News | September 05, 2024
Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
This strategic decision will unlock significant value for our scientific and industrial products business
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Subscribe To Our Newsletter & Stay Updated
